此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study in Healthy Participants With Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380

2026年11月12日 更新者:Cascade Pharmaceuticals, Inc

A Randomized, Double-blind, Placebo-controlled, Sequential, Multiple Ascending Dose (MAD) Study Following Oral Administration in Healthy Participants With Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380

A study in Healthy Participants with Elevated LDL-C to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS060380.

研究概览

详细说明

This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, PK and PD of CS060380 following oral multiple ascending dose administration in healthy participants with elevated LDL-C.

Approximately 30 participants (10 participants per cohort: n=8 participants will receive active CS060380 and n=2 participants will be administered placebo) will be enrolled sequentially in 3 ascending dose groups. The proposed dose levels will range from 1.0 mg to 4.0 mg.

The next higher dose cohort will be enrolled only after the prior dose cohort has been discharged from the CPC on Day 17 and the SRC has reviewed all available safety/tolerability, PK/PD, and thyroid function data.

研究类型

介入性

注册 (估计的)

30

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. The participant provided signed and dated informed consent.

  2. Male or female aged 18-65 years (inclusive).

  3. Fasting LDL-C >110 mg/dL (2.85 mmol/L) at screening.

  4. Female participants must meet one of the following:

    1. Postmenopausal status confirmed by follicle-stimulating hormone (FSH) testing, or
    2. Surgically sterile (medically documented), or
    3. If with childbearing potential, the participant must agree to use at least one highly effective contraceptive method in combination with an additional effective contraceptive method from study initiation until 3 months after the last dose, or
    4. Complete abstinence (if agreed by the participant).

    Male participants, even if surgically sterilized (e.g., vasectomy), must:

    1. Use effective barrier contraception and refrain from sperm donation throughout the study and for 3 months after the last dose, or
    2. Complete abstinence (if agreed upon by the participant). Refer to Section 9.4 for detailed contraceptive requirements.
  5. Normal renal function (estimated glomerular filtration rate [eGFR] ≥ 80 mL/min/1.73 m², calculated using the CKD-EPI equation).

  6. Good general health, as judged by the Investigator based on: medical/surgical history, complete physical examination, vital signs, laboratory tests, and 12-lead ECG results (all findings either normal or with no clinically significant abnormalities).

  7. No significant medical history; assessed to be in good general health at screening, with evaluations completed ≤ 28 days before the first dose.

  8. Willingness and ability to: Understand and comply with study procedures/restrictions, complete the trial as planned and communicate effectively with the Investigator.

Exclusion Criteria:

  1. Individuals with special dietary requirements unable to comply with standardized diets.

  2. Females who are pregnant or lactating, those with pregnancy plans within 3 months post-trial, or female participants with positive pregnancy tests during screening/baseline periods.

  3. Participants with febrile illness or active infection within 7 days prior to the first dose of the investigational drug.

  4. Participants with positive urine drug screening results.

  5. Participants with a history of drug/substance abuse within 5 years prior to the trial or positive drug screening at Day -1.

  6. Participants receiving lipid-lowering therapy or with LDL-C > 190 mg/dL, or those with a history of coronary artery disease, cardiac arrhythmias, unexplained syncope, or family history of sudden cardiac arrest.

  7. Participants with a history of QTc prolongation:

    1. QTcF ≥ 450 ms during screening;
    2. Hypocalcemia or family history of long QT syndrome;
    3. Use of QT/QTc-prolonging medications;
    4. ECG abnormalities deemed clinically significant by the Investigator.
  8. Tobacco or nicotine product use within 3 months prior to screening or during the study until discharge.

  9. Use of other investigational drugs within 40 days prior to enrollment or within ≥ 5 half-lives (whichever is longer).

  10. Positive infectious disease screening results during screening (HIV antibody, HBsAg, HCV antibody).

  11. Clinically significant laboratory abnormalities per Investigator judgment during screening.

  12. Presence of clinically significant hypertension, defined as systolic blood pressure (SBP) > 145 mmHg and/or diastolic blood pressure (DBP) > 90 mmHg, at Screening or Admission.

  13. Blood loss > 50 mL within 40 days or > 500 mL within 56 days prior to dosing.

  14. Regular alcohol consumption (> 1 unit/day) within 1 month prior to screening or positive alcohol test at screening or admission. [1 unit = 150 mL wine, 360 mL beer, or 45 mL 40% alcohol]. Alcohol consumption within 48 hours predose or during CRU stays.

  15. Prescription/OTC medication use within 14 days prior to admission (Day -1) or ≥ 5 half-lives (whichever is longer); or use of any of the inhibitors or induces as listed in Appendix 1, CYP3A-, p-glycoprotein- (p-gp) or breast cancer resistance protein (BCRP)-modulating substances (e.g., herbs, grapefruit) within 14 days predose or ≥ 5 half-lives.

  16. Thyroid disease history or clinically significant thyroid test abnormalities.

  17. Hypersensitivity to thyroid medications.

  18. Conditions potentially affecting drug ADME (e.g., gastrectomy, cholecystectomy, inflammatory bowel disease).

  19. Clinically significant comorbidities (e.g., GI, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular diseases) that may compromise study conduct/interpretation or pose risks per Investigator assessment.

  20. Hypersensitivity to investigational drug components, specific allergy history (asthma, urticaria, eczema), or atopic predisposition (allergy to ≥ 2 drugs/foods like milk/pollen).

  21. Any condition deemed by the Investigator to jeopardize participant safety or study integrity.

  22. Abnormal thyroid function tests (total/free T3, total/free T4, TSH) beyond reference ranges during screening.

  23. Troponin > ULN during screening or Day -1 periods.

  24. Presence of any psychiatric disorder or impaired mental capacity that may compromise the ability to provide informed consent, affect the assessment of efficacy, or impair compliance with the study protocol.

  25. Any other condition that, in the opinion of the investigator, may jeopardize the safety of the subject or compromise the quality of the clinical study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:MAD Cohort 1: CS060380 1.0 mg

CS060380 1.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions.

CS060380 is administered orally once daily (QD)

Matching placebo is administered orally once daily (QD)

其他名称:
  • CS060380 Placebo
实验性的:MAD Cohort 2: CS060380 2.0 mg

CS060380 2.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions.

CS060380 is administered orally once daily (QD)

Matching placebo is administered orally once daily (QD)

其他名称:
  • CS060380 Placebo
实验性的:MAD Cohort 3: CS060380 4.0 mg

CS060380 4.0 mg will be administered orally once daily (QD) on Days 1-14. Within this cohort (n=10), participants are randomized 8 active : 2 placebo under double-blind conditions.

CS060380 is administered orally once daily (QD)

Matching placebo is administered orally once daily (QD)

其他名称:
  • CS060380 Placebo

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Adverse Events during the study period
大体时间:Baseline to Day28

To characterize the safety and tolerability of multiple doses of CS060380 in healthy participants

Baseline to Day28

次要结果测量

结果测量
措施说明
大体时间
Cmax
大体时间:Day1

Pharmacokinetics: Maximum concentration during a dosing interval

Day1
Tmax
大体时间:Day1 Day17

Pharmacokinetics: Time to maximum plasma concentration

Day1 Day17
t1/2
大体时间:Day1

Pharmacokinetics: Terminal elimination half-life

Day1
AUClast
大体时间:Day1

Pharmacokinetics: AUC from time 0 to the last measurable concentration

Day1
AUCinf
大体时间:Day1

Pharmacokinetics: area under the plasma concentration-time curve from time zero to infinity

Day1
CL/F
大体时间:Day1

Pharmacokinetics: apparent total plasma clearance

Day1
Cmax,ss
大体时间:Day14

Pharmacokinetics: steady-state maximum plasma concentration

Day14
Cmin
大体时间:Day14

Pharmacokinetics: minimum concentration during a dosing interval

Day14
t1/2,ss
大体时间:Day14

Pharmacokinetics: steady-state terminal elimination half-life

Day14
AUCτ (τ = 24 hours)
大体时间:Day14

Pharmacokinetics: AUC from time 0 to 24 hours after dosing

Day14
CL/Fss
大体时间:Day14

Pharmacokinetics: steady-State apparent total plasma clearance

Day14
DF
大体时间:Day14

Pharmacokinetics: degree of fluctuation

Day14
Cavg
大体时间:Day14

Pharmacokinetics: mean plasma concentration during a dosing interval

Day14
Rac_AUCτ
大体时间:Day14

Pharmacokinetics: accumulation ratio based on area under the plasma concentration-time curve

Day14

其他结果措施

结果测量
措施说明
大体时间
LDL-C
大体时间:Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

Pharmacodynamics: low-density lipoprotein cholesterol

Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
HDL-C
大体时间:Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

Pharmacodynamics: high-density lipoprotein cholesterol

Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
TG
大体时间:Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

Pharmacodynamics: triglycerides

Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
TC
大体时间:Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

Pharmacodynamics: total cholesterol

Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
SHBG
大体时间:Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17

Pharmacodynamics: sex hormone binding globulin

Day 1, Day 3, Day 7, Day 10, Day 14, Day 15, Day 17
Total/free T3
大体时间:Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

To explore the effects on thyroid function parameters of CS060380

Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
total/free T4,
大体时间:Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

To explore the effects on thyroid function parameters of CS060380

Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17
TSH
大体时间:Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

To explore the effects on thyroid function parameters of CS060380

Day 3, Day 7, Day 10, Day 14, Day 15. and Day 17

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Mary Purucker, MD、Pharmaron Clinical Pharmacology Center (CPC), Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2027年3月15日

研究完成 (估计的)

2027年4月15日

研究注册日期

首次提交

2026年11月5日

首先提交符合 QC 标准的

2026年11月12日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • CS060380-MASH-US-I-05

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅